Intravitreal MCO-010 optogenetic therapy in adults with retinitis pigmentosa (RESTORE)
Retinitis Pigmentosa
Enrolment: 27 · Results not recorded
Loading the evidence…
Procedure · ChEMBL NOT QUERIED: opsin gene delivery plus light stimulation, no chemical entity; resolved=false by entity class. 14 CTgov hits for 'optogenetic', ALL ophthalmic: intravitreal opsin gene therapy for retinitis pigmentosa, Stargardt disease or choroideremia. CLASS-LEVEL FLAG: no human trial delivers 473 nm light by fibre optic cable to channelrhodopsin-expressing axons in an injured nervous system. NCT03326336 (GS030) is the closest analogue because it pairs the gene therapy with an external light-stimulating medical device.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Retinitis Pigmentosa
Enrolment: 27 · Results not recorded
Stargardt Disease
Enrolment: 6 · Results not recorded
Non-syndromic Retinitis Pigmentosa
Enrolment: 10 · Results not recorded
Stargardt Disease
Enrolment: 18 · Results not recorded
Retinitis Pigmentosa · Choroideremia
Enrolment: 10 · Results not recorded
Retinitis Pigmentosa
Enrolment: 12 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Bilateral sciatic nerve transection with end-to-end repair secured using fibrin glue
A single 1 h optical treatment increased EMG responses, motor endplate re-occupation and the number of regenerating motoneurons at 4 weeks, with the effect confined to optically activated ChR2-positive axons.
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.